Showing results (91-100 of 366) with videos related to
Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)Giuseppe Giaccone, Channa Debruyne, Enriqueta Felip, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2024
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLCMauricio Burotto, Zanete Zvirbule, Renzo Alvarez, et al.Cancer Chemotherapy and Pharmacology|February 24, 2016
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studiesDavid Planchard, Kathryn H Brown, Dong-Wan Kim, et al.Lung Cancer (Amsterdam, Netherlands)|March 17, 2022
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancerArmando Santoro, Wu-Chou Su, Alejandro Navarro, et al.Lung Cancer (Amsterdam, Netherlands)|July 27, 2025
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical expertsNancee Pronsati, Geoffrey Liu, Todd M Bauer, et al.Journal for Immunotherapy of Cancer|April 28, 2022
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLCJoan Frigola, Caterina Carbonell, Patricia Irazno, et al.Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapyEnriqueta Felip, Federico Rojo, Martin Reck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung CancerBenjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, et al.Eclinicalmedicine|July 1, 2021
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trialGlenwood D Goss, Manuel Cobo, Shun Lu, et al.Pageof 37